We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL‐class fusion.
- Authors
Moorman, Anthony V.; Schwab, Claire; Winterman, Emily; Hancock, Jerry; Castleton, Anna; Cummins, Michelle; Gibson, Brenda; Goulden, Nick; Kearns, Pam; James, Beki; Kirkwood, Amy A.; Lancaster, Donna; Madi, Mabrouk; McMillan, Andrew; Motwani, Jayashree; Norton, Alice; O'Marcaigh, Aengus; Patrick, Katharine; Bhatnagar, Neha; Qureshi, Amrana
- Abstract
Patients with an ABL‐class fusion have a high risk of relapse on standard chemotherapy but are sensitive to tyrosine kinase inhibitors (TKI). In UKALL2011, we screened patients with post‐induction MRD ≥1% and positive patients (12%) received adjuvant TKI. As the intervention started during UKALL2011, not all eligible patients were screened prospectively. Retrospective screening of eligible patients allowed the outcome of equivalent ABL‐class patients who did and did not receive a TKI in first remission to be compared. ABL‐class patients who received a TKI in first remission had a reduced risk of relapse/refractory disease: 0% vs. 63% at four years (P = 0·009).
- Subjects
PROTEIN-tyrosine kinase inhibitors; LYMPHOBLASTIC leukemia; ACUTE leukemia; TEENAGERS; ANAPLASTIC lymphoma kinase
- Publication
British Journal of Haematology, 2020, Vol 191, Issue 5, p844
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.17093